Effect of Combined Carvedilol-Pravastatin Treatment on Cardiac Function of Patients with Coronary Heart Disease and Chronic Heart Failure

Objective To investigate the effect of combined carvedilol-pravastatin treatment on N-terminal pro-brain natriuretic peptide(NT-proBNP) and cardiac troponin I(cTnI) levels and cardiac function of patients with coronary heart disease and chronic heart failure.Methods A total of 183 patients with coronary heart disease and heart failure were randomly divided into the carvedilol group(63 cases),the pravastatin group(58 cases) and joint carvedilol-pravastatin group(62 cases).These groups were administrated with the corresponding drugs besides the conventional anti-failure therapy for 12 weeks.The heart function classification according to New York Heart Association(NYHA),the blood pressure and heart rate were measured before and after treatment.The left ventricular end-diastolic diameter(LVEDD),left ventricular systolic final inner diameter(LVESD) and left ventricular ejection fraction(LVEF) were measured by echocardiography.The 6-minute walk test(6-MWT) was performed before and after treatment.The NT-proBNP and cTnI levels were tested by enzyme-linked immunosorbent assay(ELISA).The eadmission rates and incidence of cardiovascular events in three months were observed.Results After 12 weeks of treatment,LVEF,LVEDD,LVESD,blood pressure and heart rate in all the 3 groups were significantly improved(P0.05),the plasma NT-proBNP and cTnI levels were significantly decreased(P0.05),and 6-MWT were significantly increased(P0.05).The treatment effect was the most obvious,the re-hospitalization rates and the incidence of cardiovascular events was the lowest in the joint carvedilol-pravastatin group(P0.05).Conclusion Combined utilization of carvedilol and ravastatin can reduce the NT-proBNP and cTnI levels and improve the cardiac function of patients with coronary heart disease and chronic heart failure.